Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAd3-Marburg Vaccine in Healthy Adults
NCT06620003Phase 2Active, not recruiting
- Sponsor
- Sabin Vaccine Institute
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ChAd3-MARV in Marburg virus disease (MVD), sponsored by Sabin Vaccine Institute. Started Apr 2025; status: active, not recruiting.
02
Drugs
ChAd3-MARV
03
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT06620003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620003.